This amount is in addition to the nearly $12 million in series B financing the company recently raised. It plans to use the funds for two clinical trials to further prove the efficacy of Mi-eye, Trice Medical’s proprietary visualization device. The FDA-cleared device aims to help physicians perform diagnostic arthroscopies, according to the report.
More articles on devices:
5 things to know about the SpineGuard “smart screw” European patent
Medtronic Spinal employees rack-up 4.8k charitable hours — 5 things to know
X-Bolt Orthopaedics receives U.S. patent for jig device in hip nailing system
